ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aflibercept

Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.

Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.

Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 201286 company-led studies, 5 open or runningNext primary completion: Jul 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals251 open or runningphase 4since Nov 2, 2012May 13, 2002none ahead
Bayerits history only230 open or runningphase 4since Apr 10, 2014Mar 12, 2008none ahead
Sanofiits history only200 open or runningphase 3since May 16, 2006Jan 30, 2006none ahead
Novartisits history only40 open or runningphase 4since Jul 22, 2016Jul 22, 2016none ahead
Amgenits history only31 open or runningphase 3since Feb 13, 2020Feb 13, 2020Jul 31, 2027phase 3 · NCT07614776
Sam Chun Dang Pharm.its history only20 open or runningphase 3since Jul 17, 2020Jul 17, 2020none ahead
AbbVieits history only11 open or runningphase 2since Mar 16, 2022Mar 16, 2022Jun 2031phase 2 · NCT05296447
AO GENERIUMits history only11 open or runningphase 3since Sep 18, 2026Sep 18, 2026May 2028phase 3 · NCT07844148
Bioeqits history only10 open or runningphase 3since Aug 11, 2020Aug 11, 2020none ahead
Cinnagenits history only10 open or runningphase 3since Sep 18, 2022Sep 18, 2022none ahead

Also a collaborator on its studies: REGENXBIO and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 11 studies since May 13, 2002.

  1. Jul 10, 2009Phase 3 study in Macular EdemaNCT00943072 · 189 enrolled · United States, Canada, Colombia and more
  2. Aug 20, 2009Phase 3 study in Macular DegenerationNCT00964795 · 323 enrolled · United States, Canada
  3. May 27, 2011Phase 3 study in Diabetic RetinopathyNCT01363440 · 466 enrolled · United States
  4. Jan 26, 2012Phase 3 study in Retinal Vein OcclusionNCT01521559 · 183 enrolled · United States, Canada, Japan
  5. Nov 2, 2012Phase 4 study in Macular DegenerationNCT01722045 · 154 enrolled · United States
  6. Apr 13, 2015Phase 2 study in Neovascular Age-Related Macular DegenerationNCT02418754 · 505 enrolled · United States, Japan
  7. Mar 14, 2016Phase 2 study in Diabetic Macular EdemaNCT02712008 · 302 enrolled · United States
  8. Mar 20, 2016Phase 3 study in Nonproliferative Diabetic RetinopathyNCT02718326 · 402 enrolled · United States, Germany, Hungary and more
  9. Dec 5, 2018Phase 4 study in Chorioretinal Vascular DiseaseNCT03767738 · 65 enrolled · United States
  10. Sep 23, 2019Phase 3 study in Retinopathy of PrematurityNCT04101721 · 127 enrolled · United States, Bulgaria, Colombia and more
  11. Oct 11, 2019Phase 2 study in Macular DegenerationNCT04126317 · 106 enrolled · United States, Puerto Rico
  12. May 26, 2020Phase 3 study in Diabetes Mellitus, Type 1NCT04429503 · 660 enrolled · United States, Canada, Czechia and more
  13. Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127
  14. Aug 3, 2023Phase 3 study in Diabetic Macular Edema (DME)NCT05989126 · 35 enrolled · United States
  15. Jul 1, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationNCT06491914 · 1,126 enrolled · United States, Puerto Rico

TargetBeta

PGF →VEGFA →read by rule
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule

Studies

All 25 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06491914Neovascular Age-Related Macular Degeneration · United States, Puerto Rico3Active, not recruitingAug 26, 20251,126
NCT05989126Diabetic Macular Edema (DME) · United States3CompletedMay 31, 202435
NCT04429503Diabetes Mellitus, Type 1 · United States, Canada, Czechia and more3CompletedMay 30, 2022660
NCT04126317Macular Degeneration · United States, Puerto Rico2CompletedMay 14, 2021106
NCT04101721Retinopathy of Prematurity · United States, Bulgaria, Colombia and more3CompletedAug 18, 2022127
NCT03767738Chorioretinal Vascular Disease · United States4CompletedAug 19, 202065
NCT02718326Nonproliferative Diabetic Retinopathy · United States, Germany, Hungary and more3CompletedAug 6, 2018402
NCT02712008Diabetic Macular Edema · United States2CompletedJul 10, 2017302
NCT02418754Neovascular Age-Related Macular Degeneration · United States, Japan2TerminatedAug 17, 2016505
NCT01722045Macular Degeneration · United States4CompletedSep 2015154
NCT01521559Retinal Vein Occlusion · United States, Canada, Japan3CompletedAug 2013183
NCT01363440Diabetic Retinopathy · United States3CompletedJan 2013466
NCT00964795Macular Degeneration · United States, Canada3CompletedAug 2013323
NCT00943072Macular Edema · United States, Canada, Colombia and more3CompletedOct 2010189
NCT00794417Carcinoma, Non-Small-Cell Lung · United States, Canada2TerminatedJun 30, 201160
NCT00789477Diabetic Macular Edema · United States, Austria, Canada2CompletedDec 2009221
NCT00509795Macular Degeneration · United States, Canada3CompletedSep 20101,217
NCT00383370Neovascular Age Related Macular Degeneration · United States1CompletedSep 200720
NCT00320814Diabetic Macular Edema · United States1CompletedAug 20065
NCT00320788Macular Degeneration · United States2CompletedJun 2008159
NCT00320775Macular Degeneration · United States1CompletedJun 200851
NCT00083213Neoplasms · United States1CompletedMay 200825
NCT00082823Neoplasms · United States1CompletedMay 200825
NCT00045266Lymphoma · United States1CompletedFeb 2007
NCT00036946Lymphoma · United States1CompletedMar 2002

How it is read

Names in the registry

  • “Aflibercept”, 9 entries
  • “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
  • “aflibercept”, 7 entries
  • “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries

Codes read as this program: BAY865321, SCD411.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.